We are live on ! Find out more
ACM

Atika Capital Management Portfolio holdings

AUM $796M
1-Year Est. Return 167.57%
This Fund
S&P 500
This Quarter Est. Return
+13.42%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$259M
AUM Growth
-$89.4M
Cap. Flow
-$130M
Cap. Flow %
-50.25%
Top 10 Hldgs %
30.79%
Holding
94
New
15
Increased
16
Reduced
26
Closed
29

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$8.83M
2
MLM icon
Martin Marietta Materials
MLM
+$4.82M
3
ASIX icon
AdvanSix
ASIX
+$4.5M
4
ELV icon
Elevance Health
ELV
+$3.51M
5
BLUE
bluebird bio
BLUE
+$2.9M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$17.8M
2
ALGN icon
Align Technology
ALGN
+$7.72M
3
LOXO
Loxo Oncology, Inc
LOXO
+$4.14M
4
TLND
Talend S.A. American Depositary Shares
TLND
+$4.09M
5
ALB icon
Albemarle
ALB
+$3.95M

Sector Composition

Rank Sector Weight
1 Healthcare 32.38%
2 Technology 17.21%
3 Communication Services 14.84%
4 Consumer Discretionary 6.43%
5 Financials 5.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
76
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-400,000
Closed -$58.2M
SAGE
77
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-15,000
Closed -$935K
XBI icon
78
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-245,000
Closed -$21.2M
SUM
79
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
– –
-76,827
Closed -$2.39M
SLCA
80
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
– –
-35,000
Closed -$1.09M
MRNS
81
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-32,250
Closed -$869K
SIOX
82
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-3,175
Closed -$174K
REED
83
DELISTED
Reeds, Inc. Common Stock
REED
– –
-563
Closed -$62K
CALA
84
DELISTED
Calithera Biosciences, Inc
CALA
– –
-11,730
Closed -$3.69M
TLND
85
DELISTED
Talend S.A. American Depositary Shares
TLND
– –
-100,000
Closed -$4.09M
MYOK
86
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-56,000
Closed -$2.4M
IMMU
87
DELISTED
Immunomedics Inc
IMMU
– –
-135,000
Closed -$1.89M
AKCA
88
DELISTED
Akcea Therapeutics Inc
AKCA
– –
-90,000
Closed -$2.49M
MDCO
89
CALL
DELISTED
Medicines Co
MDCO
– –
-20,000
Closed -$740K
MDCO
90
DELISTED
Medicines Co
MDCO
– –
-78,000
Closed -$2.89M
MDCO
91
PUT
DELISTED
Medicines Co
MDCO
– –
-110,000
Closed -$4.08M
ONCE
92
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-23,000
Closed -$2.05M
LOXO
93
DELISTED
Loxo Oncology, Inc
LOXO
– –
-45,000
Closed -$4.14M
GIMO
94
DELISTED
Gigamon Inc.
GIMO
– –
-73,000
Closed -$3.08M
1 2 3
4

Similar funds

AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
RIM
Rovida Investment Management Grand Cayman, Cayman Islands $797M AUM 111.83% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
CAM
CenterStar Asset Management Chicago, Illinois $797M AUM 28.71% 1-Year Est. Return
Legacy Financial Group (Iowa)
Legacy Financial Group (Iowa) Des Moines, Iowa $795M AUM 12.87% 1-Year Est. Return
LSA
L & S Advisors Los Angeles, California $795M AUM 52.77% 1-Year Est. Return
GWA
Geometric Wealth Advisors Washington, District of Columbia $799M AUM 22.19% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Atika Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Atika Capital Management held 94 positions worth $259M, down 26% from $348M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Atika Capital Management withdrew a net $130M in Q4 2017, closing 29 positions and reducing 26 holdings. Its most notable exit was Loxo Oncology, Inc, an estimated $4.14M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 27% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Atika Capital Management opened a new position in Goldman Sachs worth $9.17M.

  • Atika Capital Management's largest Q4 2017 buy was Goldman Sachs: 36,000 shares worth $9.17M.
  • Atika Capital Management added most to Martin Marietta Materials in Q4 2017, an estimated $4.82M increase.
  • Atika Capital Management's biggest Q4 2017 reduction was Intuitive Surgical, cutting an estimated $17.8M.
  • Atika Capital Management fully exited Loxo Oncology, Inc in Q4 2017, selling an estimated $4.14M.
  • Atika Capital Management's ten largest holdings make up 31% of its $259M portfolio in Q4 2017.
  • Atika Capital Management opened 15 new positions and closed 29 in Q4 2017.
  • Atika Capital Management's portfolio value fell 26% quarter-over-quarter to $259M.

Based on Atika Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.